1. Scrip
  2. >>R&D

Kelun Wins World’s First TROP2 ADC Approval In Lung Cancer

 
• By Dexter Jie Yan

While diverging from partner Merck & Co. in its study dosage of sacituzumab tirumotecan, Kelun has garnered the world’s first approval, in China, for a TROP2-targeting antibody-drug conjugate, for the treatment of lung cancer.

Merck/Kelun and AstraZeneca/Daiichi Sankyo are locked in a race to win lung cancer labels for their TROP2 ADCs. (Shutterstock)

Sichuan Kelun Pharmaceutical has won an approval in China for its Merck & Co.-partnered sacituzumab tirumotecan (sac-TMT), a TROP2-targeting antibody-drug conjugate (ADC), which becomes the world’s first in the class to be cleared for the treatment of lung cancer.

While originator Kelun retains the Greater China rights to sac-TMT under a tie-up with Merck signed in 2022, its development...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from Focus On Asia